Cleared Traditional

K211715 - RetinAI Discovery (FDA 510(k) Clearance)

Class II Ophthalmic device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K211715 · Retinai Medical AG · Ophthalmic device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2022
Decision
329d
Days
Class 2
Risk

K211715 is an FDA 510(k) clearance for the RetinAI Discovery. Classified as System, Image Management, Ophthalmic (product code NFJ), Class II - Special Controls.

Submitted by Retinai Medical AG (Bern, CH). The FDA issued a Cleared decision on April 28, 2022 after a review of 329 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 892.2050 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Ophthalmic review framework, consistent with the majority of Class II 510(k) submissions.

View all Retinai Medical AG devices

Submission Details

510(k) Number K211715 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 03, 2021
Decision Date April 28, 2022
Days to Decision 329 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
219d slower than avg
Panel avg: 110d · This submission: 329d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code NFJ System, Image Management, Ophthalmic
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 892.2050
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Ophthalmic devices follow this clearance model.

Regulatory Peers - NFJ System, Image Management, Ophthalmic

All 50
Devices cleared under the same product code (NFJ) and FDA review panel - the closest regulatory comparables to K211715.
iCare ALTIUS CW
K234076 · Centervue S.P.A. · Aug 2024
IMAGEnet6 Ophthalmic Data System
K232828 · Topcon Corporation · Mar 2024
CALLISTO eye
K232944 · Carl Zeiss Meditec, AG · Dec 2023
Harmony
K232555 · Topcon Healthcare Solutions · Nov 2023
CALLISTO eye
K231676 · Carl Zeiss Meditec, AG · Aug 2023
Altris IMS
K232088 · Altris, Inc. · Jul 2023